OBJECTIVES: Anthracyclines and taxanes are often used as first-line chemotherapy treatments in patients with breast cancer. There are, however, significant toxicity and side effects associated with these therapies. Previous studies have demonstrated that active hexose-correlated compound (AHCC) reduces such side effects. The present study explored the beneficial effects of AHCC on adverse events in patients receiving adjuvant chemotherapy for breast cancer. SUBJECTS: Forty-one women who were treated with anthracyclines and taxanes at Nagumo Clinic in Tokyo from October 2004 to March 2011 were selected for this study. OUTCOME MEASURES: We compared the occurrence of adverse events in patients who received AHCC with those who did not receive AHCC. Using Fisher's exact tests, we also compared the worst-grade adverse events in each treatment cycle. Generalized estimating equations were employed to compare longitudinal changes, and the use of granulocyte colony-stimulating factor, in the two groups was analyzed using Student's t-test. RESULTS: We found that, compared to the control group, the AHCC group had significantly fewer neutrophil-related events (odds ratio, 0.30; p=0.016), significantly lower use of granulocyte colony-stimulating factor, and a higher (although not significant) rate of adverse events associated with γ-glutamyl transpeptidase. CONCLUSIONS: AHCC has the potential to reduce the severity of neutropenia induced by breast cancer chemotherapy and the use of G-CSF during chemotherapy.
OBJECTIVES:Anthracyclines and taxanes are often used as first-line chemotherapy treatments in patients with breast cancer. There are, however, significant toxicity and side effects associated with these therapies. Previous studies have demonstrated that active hexose-correlated compound (AHCC) reduces such side effects. The present study explored the beneficial effects of AHCC on adverse events in patients receiving adjuvant chemotherapy for breast cancer. SUBJECTS: Forty-one women who were treated with anthracyclines and taxanes at Nagumo Clinic in Tokyo from October 2004 to March 2011 were selected for this study. OUTCOME MEASURES: We compared the occurrence of adverse events in patients who received AHCC with those who did not receive AHCC. Using Fisher's exact tests, we also compared the worst-grade adverse events in each treatment cycle. Generalized estimating equations were employed to compare longitudinal changes, and the use of granulocyte colony-stimulating factor, in the two groups was analyzed using Student's t-test. RESULTS: We found that, compared to the control group, the AHCC group had significantly fewer neutrophil-related events (odds ratio, 0.30; p=0.016), significantly lower use of granulocyte colony-stimulating factor, and a higher (although not significant) rate of adverse events associated with γ-glutamyl transpeptidase. CONCLUSIONS: AHCC has the potential to reduce the severity of neutropenia induced by breast cancer chemotherapy and the use of G-CSF during chemotherapy.
Authors: David G Warr; Paul J Hesketh; Richard J Gralla; Hyman B Muss; Jørn Herrstedt; Peter D Eisenberg; Harry Raftopoulos; Steven M Grunberg; Munir Gabriel; Anthony Rodgers; Norman Bohidar; George Klinger; Carolyn M Hustad; Kevin J Horgan; Franck Skobieranda Journal: J Clin Oncol Date: 2005-04-20 Impact factor: 44.544
Authors: Miguel Martin; Tadeusz Pienkowski; John Mackey; Marek Pawlicki; Jean-Paul Guastalla; Charles Weaver; Eva Tomiak; Taher Al-Tweigeri; Linnea Chap; Eva Juhos; Raymond Guevin; Anthony Howell; Tommy Fornander; John Hainsworth; Robert Coleman; Jeferson Vinholes; Manuel Modiano; Tamas Pinter; Shou C Tang; Bruce Colwell; Catherine Prady; Louise Provencher; David Walde; Alvaro Rodriguez-Lescure; Judith Hugh; Camille Loret; Matthieu Rupin; Sandra Blitz; Philip Jacobs; Michael Murawsky; Alessandro Riva; Charles Vogel Journal: N Engl J Med Date: 2005-06-02 Impact factor: 91.245
Authors: Shinil K Shah; Peter A Walker; Stacey D Moore-Olufemi; Alamelu Sundaresan; Anil D Kulkarni; Richard J Andrassy Journal: JPEN J Parenter Enteral Nutr Date: 2011-05-31 Impact factor: 4.016
Authors: I Craig Henderson; Donald A Berry; George D Demetri; Constance T Cirrincione; Lori J Goldstein; Silvana Martino; James N Ingle; M Robert Cooper; Daniel F Hayes; Katherine H Tkaczuk; Gini Fleming; James F Holland; David B Duggan; John T Carpenter; Emil Frei; Richard L Schilsky; William C Wood; Hyman B Muss; Larry Norton Journal: J Clin Oncol Date: 2003-03-15 Impact factor: 44.544
Authors: Massimo Bonucci; Andrea Geraci; Dina Pero; Cristina Villivà; Daniele Cordella; Maria Condello; Stefania Meschini; Laura Del Campo; Franco Tomassi; Alessandro Porcu; Francesco De Lorenzo; Francesco Lozupone Journal: Evid Based Complement Alternat Med Date: 2022-08-01 Impact factor: 2.650
Authors: Lata Mathew; Anjali Gaikwad; Anneliese Gonzalez; Elizabeth K Nugent; Judith A Smith Journal: Integr Cancer Ther Date: 2017-04-25 Impact factor: 3.279